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STANDARD GAMBLE AND CONJOINT UTILITY
WEIGHTS:VALIDITY, FEASIBILITY,AND
USEFULNESS
Johnson FR1, Mauskopf J1, Hauber AB2
1Research Triangle Institute, Research Triangle Park, NC, USA;
2Parametric Research Corporation, Hatboro, PA, USA
OBJECTIVES: Compare and evaluate the conceptual and
numerical differences between standard gamble (SG) and
conjoint analysis (CA) utility weights.
METHODS: Reducing complex relationships among
health outcomes to a single utility index requires strong
assumptions. We compare and evaluate the required
assumptions for SG and CA utility weights using numer-
ical estimates from published SG weights and CA utility
estimates from a study of acute respiratory and cardio-
vascular symptoms. We analyze alternative mappings of
one index into the other, evaluate necessary assumptions
and restrictions, and compare empirical differences.
RESULTS: Differences in the underlying metrics and
information content of SG and CA utility indexes com-
plicate mapping one scale into the other. Even when the
scales can be deﬁned comparably for a given range of 
outcomes, extrapolating CA utility outside this range may
yield corresponding SG weights outside the 0–1 interval.
CA methods facilitate including other utility-relevant
health-care features, such as dosing frequency, employ
cognitive tasks more familiar to patients than the SG task,
and can be scaled in natural units such as money or time.
However, CA utility can vary nonlinearly by duration,
health-care process attributes, and individual characteris-
tics and thus cannot generally be summed across individ-
uals, health states, and time periods. If decision makers
require a simple, aggregate utility measure, they must
accept SG restrictions that break the correspondence
between measured utility and actual patient preferences.
CONCLUSIONS: CA utility weights have several con-
ceptual and empirical advantages relative to SG utility
weights. The perceived usefulness and practicality of SG
utility for constructing QALYs must be weighed against
the potential for providing decision makers with mis-
leading information about the net beneﬁts of health 
interventions.
PMI14
THE DEVELOPMENT OF A SEVERITY STAGING
SYSTEM FOR ECONOMIC EVALUATIONS OF
THE PROGRESSION OF GLAUCOMA
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OBJECTIVES: In order to conduct a multi-center retro-
spective chart review, with the purposes of assessing
resource utilization and the multiple costs associated with
disease progression, a glaucoma staging system (GSS) was
developed. Since no universally accepted GSS exists, par-
ticularly one that takes into account economic consider-
ations, we tested a modiﬁed system to allow for unam-
biguous stage assignment for all patients and to evaluate
the economic impact of progressing disease severity.
METHODS: A review of currently developed GSSs was
conducted and the Bascom Palmer GSS was selected as
most adaptable for economic analyses. A modiﬁed Delphi
panel of physicians specializing in glaucoma treatment
suggested modiﬁcations to the system. Consideration was
given to practical use in retrospectively staging patients
using clinical parameters available in glaucoma charts,
with the end goal of assessing the economic impact of
treating glaucoma. Modiﬁcations were made to ensure
deﬁned stages encompassed a complete severity range
from pre-diagnosis to complete blindness. The revised
GSS was pre-tested on 30 charts at one participating
center in a retrospective chart review study and ﬁnal 
modiﬁcations were made to assure certainty in patient
classiﬁcation.
RESULTS: The ﬁnal GSS comprises six stages based 
principally on visual ﬁeld parameters. End-stage disease
was deﬁned based on poor visual acuity and inability to
perform visual ﬁelds. The ﬁnalized GSS was successfully
applied to a new group of randomly selected glaucoma
charts. The instrument was able to classify all identiﬁed
glaucoma patients from normal to end-stage disease, and
facilitated resource utilization abstraction by individual
stage.
CONCLUSIONS: An improved GSS to track progression
was designed which allows staging of patients from his-
torical chart data. This GSS may be used to monitor long-
term progression and is a useful tool for the purposes of
assessing the economic impact of glaucoma progression
in categorical stages. This GSS needs to be further tested
prospectively to determine its ultimate utility in economic
evaluations.
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MATHEMATICAL MODEL (MM) OF ANTIBIOTIC
(AB) IN VITRO SUSCEPTIBILITY (SUS) OVER
THE COMPLETE RANGE OF MINIMUM
INHIBITORY CONCENTRATION (MIC)
Chambers RB, Pankey GA
Ochsner Clinic Foundation, New Orleans, LA, USA
OBJECTIVES: Simple and complex computer MMs are
being used to research infectious disease problems. Analy-
sis of in vitro AB activity is usually limited to simple com-
parison of National Committee for Clinical Laboratory
Standards (NCCLS) tube dilution SUS and MIC90.
Similar ABs with similar MIC90s for a bacterium are
assumed equal in activity. This mimics the problem of
analyzing the survival time of patients, which is solved by
statistical methods like Kaplan Meier survival table (KM)
analysis. Using AB dilution instead of time in KM analy-
ses may identify differences in SUS that cannot be found
by traditional methods. A MM was developed to test this
assumption.
